# 3D PRINTING OF A MICROFLUIDIC DEVICE FOR THE PREPARATION OF LIPIDIC NANOPARTICLES





1506 UNIVERSITÀ DEGLI STUDI DI URBINO CARLO BO

17<sup>th</sup> September 2020

### Mattia Tiboni

Department of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy




### Email: mattia.tiboni@uniurb.it



# Fused deposition modeling (FDM) 3D printing

- 3D printing technology that allow to print objects layer by layer
- Increasing interest on its application in the pharmaceutical field during the last ten years
- Production of pharmaceutical devices (patches, microneedles, stents, films, etc)
- Direct production of pharmaceutical forms (tablets, suppositories)
- Personalized medicine (Form, dosage, etc)


But it is not only direct production of pharmaceutical forms or devices....



A. Melocchi, M. Uboldi, M. Cerea, A. Foppoli, A. Maroni, S. Moutaharrik, L. Palugan, L. Zema, A. Gazzaniga, A Graphical Review on the Escalation of Fused Deposition Modeling (FDM) 3D Printing in the Pharmaceutical Field, J. Pharm. Sci. (2020). https://doi.org/10.1016/j.xphs.2020.07.011.








# Microfluidics


- Controllable and scalable technique for the production of nano or micro particles
- Precise control of micromixing under laminar flow
- One-step production
- High production rates
- Higher drug encapsulation compared to conventional techniques






## Why is convenient to produce 3D printed microfluidic chips?


- Device design by CAD software
- Material choice
- Low cost
- Complete personalization of the device
- Easy to produce
- Good resolution



## A case study UNIVERSITÀ DEGLI STUDI DI URBINO CARLO BO **3D-printed microfluidic chip for the preparation of glycyrrhetinic** acid-loaded ethanolic liposomes





M. Tiboni, S. Benedetti, A. Skouras, G. Curzi, D. Romano Perinelli, G. Filippo Palmieri, L. Casettari, 3D-printed microfluidic chip for the preparation of glycyrrhetinic acidloaded ethanolic liposomes, Int. J. Pharm. (2020) 119436. https://doi.org/10.1016/j.ijpharm.2020.119436.




## BACKGROUND


- Glycyrrhetinic acid is an active compound present in licorice
- It showed anti-inflammatory and anti-oxidant activities when applied topically
- Ethosomes are known to have an increased permeation through stratum corneum
- Production using 3D printed microfluidic chip












**Cell viability** of HaCaT cell line after incubation with unloaded liposomes and GA loaded liposomes at different concentrations for 24 h at 37 °C. The viability was determined by WST-8 and SRB assays




 $202 \pm 5.2 \text{ nm}$ Narrow size distribution Good **stability** over a period of 30 days **Encapsulation efficiency** of  $63.15 \pm 2.2\%$ ,




# RESULTS

In vitro release and permeation studies using vertical diffusion cells (VDC) with Ethanol 30% (v/v) as receptor medium (A, B). In the graphs, the GA-loaded liposomal hydrogel, the GA-loaded liposomal suspension, saturated GA hydrogel and saturated GA solution.


are represented. Cellulose dialysis membranes with a different cut-off (A) and skin mimicking Strat-M® membranes (B) were used.





# CONCLUSIONS


- Development of an ethanolic liposomal formulation encapsulating GA intended for administration with topical good physicochemical characteristics and an EE% of GA up to 63%,
- Development of a biodegradable and costeffective PLA 3D-printed microfluidic chip which represents an affordable microfluidic device with an easy fabrication, very low cost (13 g of PLA for a total cost of less than 1 US \$) and potential scalability for higher production rates (up to 900 mL/h).
- The liposomal hydrogel compared to GAsaturated hydrogel reached an almost 10x times higher drug release and an 8x times higher drug permeation across skin mimicking Strat-M® membranes that could represent a methodology using VDC, reproducible alternative to ex-vivo skin in diffusion studies.



References: Pastorino G, Cornara L, Soares S, Rodrigues F Oliveira. M.B.P.P. 2018:2323–2339. Martins J P, Torrieri G, Santos H A. Expert Opin. Drug Deliv. 2018:469-479. Tiboni M, Benedetti S, Skouras A, Curzi G, Romano Perinelli D,

Palmieri G F, Casettari L. Int. J. Pharm. 2020:584, 119436

# Aknowledgements





University of Urbino Carlo Bo

- Prof. Luca Casettari
- Dr. Serena Benedetti

University of Camerino

- Prof. Giovanni Filippo Palmieri
- Dr. Diego Romano Perinelli



## Prosopika s.r.l.

Dr. Giulia Curzi



Idrofoglia s.r.l.

Tech. HSD Massimiliano Tiboni



## **European University Cyprus** Dr. Athanasios Skouras •



For any questions: mattia.tiboni@uniurb.it

# Thank you for your attention

### **URBINO Unesco Heritage**









1506 UNIVERSITÀ DEGLI STUDI DI URBINO CARLO BO

